<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Med Biol Res</journal-id><journal-id journal-id-type="iso-abbrev">Braz. J. Med. Biol. Res</journal-id><journal-id journal-id-type="publisher-id">bjmbr</journal-id><journal-title-group><journal-title>Brazilian Journal of Medical and Biological Research</journal-title></journal-title-group><issn pub-type="ppub">0100-879X</issn><issn pub-type="epub">1414-431X</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Divulga&#x000e7;&#x000e3;o Cient&#x000ed;fica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26176313</article-id><article-id pub-id-type="pmc">4568812</article-id><article-id pub-id-type="doi">10.1590/1414-431X20154676</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Investigation</subject></subj-group></article-categories><title-group><article-title>Preventive effect of reduced glutathione on contrast-induced nephropathy
in elderly patients undergoing coronary angiography or intervention: a randomized,
controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jin</surname><given-names>B.</given-names></name><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>B.W.</given-names></name><xref ref-type="author-notes" rid="fn1">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>J.J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>X.P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>H.M.</given-names></name></contrib><aff>Department of Cardiology, Huashan Hospital, Fudan University, Shanghai,
<country>China</country></aff></contrib-group><author-notes><corresp>Correspondence: Hai-Ming Shi: <email>shihmhs@aliyun.com</email>.</corresp><fn id="fn1" fn-type="conflict"><p>*These authors contributed equally to this study.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>7</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2015</year></pub-date><volume>48</volume><issue>9</issue><fpage>839</fpage><lpage>842</lpage><history><date date-type="received"><day>8</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p></license></permissions><abstract><p>Coronary angiography can be a high-risk condition for the incidence of
contrast-induced nephropathy (CIN) in elderly patients. Reduced glutathione, under a
variety of mechanisms, may prevent CIN in this procedure. We prospectively examined
whether hydration with reduced glutathione is superior to hydration alone for
prevention of CIN in an elderly Han Chinese population. A total of 505 patients (271
males and 234 females) aged 75 years or older who underwent non-emergency coronary
angiography or an intervention were randomly divided into two groups. The treatment
group received hydration with reduced glutathione (n=262) and the control group
received hydration alone (n=243). Serum creatinine and blood urea nitrogen levels
were measured prior to coronary angiography and 48 h after this procedure. The
primary endpoint was occurrence of CIN, which was defined as 25% or 44.2 &#x000b5;mol/L above
baseline serum creatinine levels 48 h after the procedure. The overall incidence of
CIN was 6.49% in the treatment group and 7.41% in the control group, with no
significant difference between the groups (P=0.68). In subgroup analysis by
percutaneous coronary intervention, no significant differences were found between the
two groups. In summary, reduced glutathione added to optimal hydration does not
further decrease the risk of CIN in elderly patients undergoing coronary angiography
or an intervention.</p></abstract><kwd-group><kwd>Contrast-induced nephropathy</kwd><kwd>Reduced glutathione</kwd><kwd>Randomized, controlled trial</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><equation-count count="0"/><ref-count count="20"/><page-count count="4"/></counts></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Contrast-induced nephropathy (CIN) is one of the complications of contrast media, which
are used in diagnostic and interventional cardiology procedures. CIN is recognized as an
important clinical problem following coronary angiography and percutaneous coronary
intervention (PCI) in recent years. Therefore, an increase in the incidence of CIN has
resulted in it being the third most common cause of hospital-acquired acute kidney
injury (<xref rid="B01" ref-type="bibr"/>
<xref rid="B02" ref-type="bibr"/>
<xref rid="B03" ref-type="bibr">13</xref>).</p><p>Effective prophylactic and therapeutic regimens for decreasing the incidence of CIN are
limited. Therefore, additional strategies are urgently required. However, except for
intravenous hydration, the optimal strategy for preventing CIN remains uncertain (<xref rid="B04" ref-type="bibr"/>
<xref rid="B05" ref-type="bibr"/>
<xref rid="B06" ref-type="bibr">46</xref>). Because oxidative stress has been implicated
as a contributing factor in the etiology of CIN (<xref rid="B07" ref-type="bibr"/>
<xref rid="B08" ref-type="bibr"/>
<xref rid="B09" ref-type="bibr">79</xref>), use of a potent antioxidant as a
nephroprotective agent is logical. Reduced glutathione, under a variety of mechanisms,
may prevent CIN. Limited information is available about the potential preventive
benefits of reduced glutathione for CIN in the elderly Han Chinese population.
Therefore, we prospectively examined whether hydration with reduced glutathione is
superior to hydration alone for prevention of CIN in a randomized, controlled trial.</p></sec><sec sec-type="materials|methods"><title>Material and Methods</title><sec><title>Study population</title><p>This study was carried out at Huashan Hospital, Fudan University between February
2012 and January 2014. Eligibility for the study was defined as patients aged &#x02265;75
years and those who had an estimated glomerular filtration rate &#x02265;60 mL/min/1.73
m<sup>2</sup> who underwent non-emergency coronary angiography or intervention.
Exclusion criteria were acute myocardial infarction, congestive heart failure, and
hemodynamic instability during the procedure. A total of 505 patients (271 males and
234 females) aged 75 years or older were eligible. The ethics review board of Huashan
Hospital approved the study protocol, and written informed consent was obtained from
all participants in the study.</p></sec><sec><title>Study design</title><p>This was a non-blinded, randomized, controlled clinical trial among the Han
population aged 75 years or older. Consecutive eligible patients were randomly
allocated to 2 groups: patients receiving saline plus reduced glutathione (n=262) or
saline alone (n=243). Randomization was based upon computer-generated randomization
numbers. No placebo was used in this randomized, controlled, clinical trial. The
hydration protocol consisted of 1 mL/kg per h of saline for 6 h prior to, during, and
6 h after the procedure. Reduced glutathione (Shanghai Fudan Forward S&#x00026;T Co.,
Ltd, China) was administered at the dosage of 2400 mg in saline on the day of the
procedure. All of the patients received a non-ionic, iso-osmolar contrast agent
(Shanghai Bracco Sine Pharmaceutical Co., Ltd, China) during the procedure. Serum
creatinine and blood urea nitrogen levels were measured prior to the procedure and 48
h after the procedure by the same technician in the same laboratory. Paraclinical
evaluations were performed in a single hospital laboratory, and laboratory staff were
blinded to the study protocol. The primary endpoint of the study was the occurrence
of CIN, which was defined as a minimum of 0.5 mg/dL or 25% increase in serum
creatinine levels above the baseline 48 h after exposure to contrast media.</p></sec><sec><title>Statistical analysis</title><p>Continuous variables with normal distribution are reported as means&#x000b1;SD. Comparisons
between the two groups were performed by the Student&#x02019;s <italic>t</italic>-test. Data
analysis was performed with SPSS 12.0. P&#x0003c;0.05 was considered to be
significant.</p></sec><sec sec-type="results"><title>Results</title><p>Demographic data of the patients are summarized in <xref ref-type="table" rid="t01">Table 1</xref>. The two study groups were generally similar in demographic and
baseline characteristics.</p><table-wrap id="t01" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-09-00839-gt001"/></table-wrap><p>The estimated glomerular filtration rate was not significantly different between the
treatment group (72.08&#x000b1;8.31 mL/min/1.73 m<sup>2</sup>) and the hydration group
(74.63&#x000b1;9.55 mL/min/1.73 m<sup>2</sup>, <xref ref-type="table" rid="t02">Table
2</xref>, P=0.64). Similarly, serum creatinine and blood urea nitrogen levels were
not significantly different between the two groups after exposure to contrast
media.</p><table-wrap id="t02" orientation="portrait" position="float"><graphic xlink:href="1414-431X-bjmbr-48-09-00839-gt002"/></table-wrap><p>The overall incidence of CIN was 6.93% (35/505) in the Han population aged 75 years
or older who underwent coronary angiography or intervention. The incidence of CIN was
similar in both groups (6.49% [17/262] in the treatment group versus 7.43% [18/243]
in the control group, P=0.68). In subgroup analysis by PCI, no significant
differences were found between the two groups (<xref ref-type="table" rid="t02">Table
2</xref>). No patients required renal replacement therapy during or after the
study. There was no mortality in either group during hospitalization.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The main finding of our study was that, although reduced glutathione tended to reduce
the occurrence of CIN, this reduction was not significant in elderly patients. Our
clinical trial is the first study on the role of reduced glutathione in prevention of
CIN in a Han population aged 75 years or older. The patients&#x02019; demographic data and
baseline risk factors for CIN were similar in the two groups. The overall incidence
of CIN is consistent with previous studies in which saline hydration was used as a
preventive measure (<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>). Therefore, the lower incidence of CIN with hydration
compared with its incidence in medically unprotected conditions is due to the
effective hydration protocol.</p><p>The pathophysiology of CIN is unclear. Contrast-induced renal dysfunction appears to
be due to a reduction in renal blood flow and direct tubular epithelial toxicity
(<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>). As a potent antioxidant, reduced glutathione may counteract various
pathological mechanisms underlying CIN (<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>). Additionally, glutathione
can reduce inflammation, inhibit oxidative stress reactions, and protect the kidney
from injury due to complement activation (<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Results of previous studies are controversial regarding the preventive effects of
reduced glutathione against CIN (<xref rid="B18" ref-type="bibr">18</xref>,<xref rid="B19" ref-type="bibr">19</xref>). We found no protective effect of reduced
glutathione on serum creatinine levels after contrast material injection. Notably,
the present study was conducted on elderly patients with a normal renal function who
underwent coronary angiography or intervention.</p><p>Even minimal changes in post-procedural serum creatinine levels are associated with
increased mortality in patients undergoing coronary angiography (<xref rid="B20" ref-type="bibr">20</xref>). Although these changes may be clinically
subtle in terms of manifestations, they may signify a great decline in renal function
in elderly patients. In the current trial, serum creatinine was studied in both
groups. No significant difference in serum creatinine levels was observed between the
groups in this study.</p><p>Some limitations of our study should be acknowledged. First, the trial was a
single-center study, which may reduce its generalizability. Second, the small sample
size may have impaired the statistical power of the study in detecting a difference
between the groups. Significance might be achieved in larger populations. Third, we
did not measure markers of oxidative stress in the present study because of the high
cost involved. Finally, short-term administration of hydration with reduced
glutathione resulted in a low rate of events in elderly patients with a normal renal
function. Further clinical trials in patients with renal impairment are warranted to
define the role of hydration with reduced glutathione.</p><p>In conclusion, the present study indicated that reduced glutathione added to optimal
hydration does not further decrease the risk of CIN in elderly patients undergoing
coronary angiography or intervention. However, despite these negative results, a
causal relationship may exist in the development of CIN. Well-designed studies with a
larger sample size and longer follow-up should be conducted to confirm our
results.</p></sec></sec></body><back><ack><p>We gratefully acknowledge Dr. Ying Shan for her editorial suggestions for the article.
This study was supported in part by a grant from the National Natural Science Foundation
in China (#81470496).</p></ack><fn-group><fn fn-type="other"><p>First published online.</p></fn></fn-group><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeder</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>M</given-names></name><name><surname>Fehr</surname><given-names>T</given-names></name><name><surname>Rickli</surname><given-names>H</given-names></name></person-group><article-title>Contrast nephropathy: review focusing on
prevention</article-title><source>J Am Coll Cardiol</source><year>2004</year><volume>44</volume><fpage>1763</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.075</pub-id><pub-id pub-id-type="pmid">15519005</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>NM</given-names></name><name><surname>Mahfouz</surname><given-names>A</given-names></name><name><surname>Achkar</surname><given-names>K</given-names></name><name><surname>Rafie</surname><given-names>IM</given-names></name><name><surname>Hajar</surname><given-names>R</given-names></name></person-group><article-title>Contrast-induced nephropathy</article-title><source>Heart Views</source><year>2013</year><volume>14</volume><fpage>106</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.4103/1995-705X.125926</pub-id><pub-id pub-id-type="pmid">24696755</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golshahi</surname><given-names>J</given-names></name><name><surname>Nasri</surname><given-names>H</given-names></name><name><surname>Gharipour</surname><given-names>M</given-names></name></person-group><article-title>Contrast-induced nephropathy; A literature
review</article-title><source>J Nephropathol</source><year>2014</year><volume>3</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.12860/jnp.2014.12</pub-id><pub-id pub-id-type="pmid">24772397</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maioli</surname><given-names>M</given-names></name><name><surname>Toso</surname><given-names>A</given-names></name><name><surname>Leoncini</surname><given-names>M</given-names></name><name><surname>Gallopin</surname><given-names>M</given-names></name><name><surname>Tedeschi</surname><given-names>D</given-names></name><name><surname>Micheletti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sodium bicarbonate versus saline for the prevention of
contrast-induced nephropathy in patients with renal dysfunction undergoing
coronary angiography or intervention</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2008.05.026</pub-id><pub-id pub-id-type="pmid">18702961</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Bie</surname><given-names>MK</given-names></name><name><surname>van Rees</surname><given-names>JB</given-names></name><name><surname>Herzog</surname><given-names>CA</given-names></name><name><surname>Rabelink</surname><given-names>TJ</given-names></name><name><surname>Schalij</surname><given-names>MJ</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name></person-group><article-title>How to reduce the incidence of contrast induced acute
kidney injury after cardiac invasive procedures, a review and practical
recommendations</article-title><source>Curr Med Res Opin</source><year>2011</year><volume>27</volume><fpage>1347</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1185/03007995.2011.580732</pub-id><pub-id pub-id-type="pmid">21561396</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davenport</surname><given-names>MS</given-names></name><name><surname>Cohan</surname><given-names>RH</given-names></name><name><surname>Khalatbari</surname><given-names>S</given-names></name><name><surname>Ellis</surname><given-names>JH</given-names></name></person-group><article-title>The challenges in assessing contrast-induced
nephropathy: where are we now?</article-title><source>AJR Am J Roentgenol</source><year>2014</year><volume>202</volume><fpage>784</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.2214/AJR.13.11369</pub-id><pub-id pub-id-type="pmid">24660707</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heyman</surname><given-names>SN</given-names></name><name><surname>Rosen</surname><given-names>S</given-names></name><name><surname>Khamaisi</surname><given-names>M</given-names></name><name><surname>Idee</surname><given-names>JM</given-names></name><name><surname>Rosenberger</surname><given-names>C</given-names></name></person-group><article-title>Reactive oxygen species and the pathogenesis of
radiocontrast-induced nephropathy</article-title><source>Invest Radiol</source><year>2010</year><volume>45</volume><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1097/RLI.0b013e3181d2eed8</pub-id><pub-id pub-id-type="pmid">20195159</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Au</surname><given-names>TH</given-names></name><name><surname>Bruckner</surname><given-names>A</given-names></name><name><surname>Mohiuddin</surname><given-names>SM</given-names></name><name><surname>Hilleman</surname><given-names>DE</given-names></name></person-group><article-title>The prevention of contrast-induced
nephropathy</article-title><source>Ann Pharmacother</source><year>2014</year><volume>48</volume><fpage>1332</fpage><lpage>1342</lpage><pub-id pub-id-type="doi">10.1177/1060028014541996</pub-id><pub-id pub-id-type="pmid">24994723</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Hou</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Short-term rosuvastatin therapy for prevention of
contrast-induced acute kidney injury in patients with diabetes and chronic kidney
disease</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.09.017</pub-id><pub-id pub-id-type="pmid">24076297</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firouzi</surname><given-names>A</given-names></name><name><surname>Eshraghi</surname><given-names>A</given-names></name><name><surname>Shakerian</surname><given-names>F</given-names></name><name><surname>Sanati</surname><given-names>HR</given-names></name><name><surname>Salehi</surname><given-names>N</given-names></name><name><surname>Zahedmehr</surname><given-names>A</given-names></name><etal/></person-group><article-title>Efficacy of pentoxifylline in prevention of
contrast-induced nephropathy in angioplasty patients</article-title><source>Int Urol Nephrol</source><year>2012</year><volume>44</volume><fpage>1145</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1007/s11255-011-0053-4</pub-id><pub-id pub-id-type="pmid">21898040</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavari</surname><given-names>V</given-names></name><name><surname>Ostovan</surname><given-names>MA</given-names></name><name><surname>Kojuri</surname><given-names>J</given-names></name><name><surname>Afshariani</surname><given-names>R</given-names></name><name><surname>Hamidian</surname><given-names>JA</given-names></name><name><surname>Roozbeh</surname><given-names>J</given-names></name><etal/></person-group><article-title>The preventive effect of pentoxifylline on
contrast-induced nephropathy: a randomized clinical trial</article-title><source>Int Urol Nephrol</source><year>2014</year><volume>46</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1007/s11255-013-0420-4</pub-id><pub-id pub-id-type="pmid">23572413</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>PA</given-names></name></person-group><article-title>Contrast-induced acute kidney injury</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>51</volume><fpage>1419</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.12.035</pub-id><pub-id pub-id-type="pmid">18402894</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>AL</given-names></name></person-group><article-title>Contrast-induced nephropathy: pathophysiology and
preventive strategies</article-title><source>Crit Care Nurse</source><year>2013</year><volume>33</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.4037/ccn2013680</pub-id><pub-id pub-id-type="pmid">23377156</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Dean</surname><given-names>O</given-names></name><name><surname>Copolov</surname><given-names>DL</given-names></name><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group><article-title>N-acetylcysteine for antioxidant therapy: pharmacology
and clinical utility</article-title><source>Expert Opin Biol Ther</source><year>2008</year><volume>8</volume><fpage>1955</fpage><lpage>1962</lpage><pub-id pub-id-type="doi">10.1517/14728220802517901</pub-id><pub-id pub-id-type="pmid">18990082</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rushworth</surname><given-names>GF</given-names></name><name><surname>Megson</surname><given-names>IL</given-names></name></person-group><article-title>Existing and potential therapeutic uses for
N-acetylcysteine: the need for conversion to intracellular glutathione for
antioxidant benefits</article-title><source>Pharmacol Ther</source><year>2014</year><volume>141</volume><fpage>150</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.09.006</pub-id><pub-id pub-id-type="pmid">24080471</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>AM</given-names></name><name><surname>Dwamena</surname><given-names>B</given-names></name><name><surname>Cronin</surname><given-names>P</given-names></name><name><surname>Bernstein</surname><given-names>SJ</given-names></name><name><surname>Carlos</surname><given-names>RC</given-names></name></person-group><article-title>Meta-analysis: effectiveness of drugs for preventing
contrast-induced nephropathy</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-148-4-200802190-00007</pub-id><pub-id pub-id-type="pmid">18283206</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Sullivan</surname><given-names>S</given-names></name><name><surname>Healy</surname><given-names>DA</given-names></name><name><surname>Moloney</surname><given-names>MC</given-names></name><name><surname>Grace</surname><given-names>PA</given-names></name><name><surname>Walsh</surname><given-names>SR</given-names></name></person-group><article-title>The role of N-acetylcysteine in the prevention of
contrast-induced nephropathy in patients undergoing peripheral angiography: a
structured review and meta-analysis</article-title><source>Angiology</source><year>2013</year><volume>64</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1177/0003319712467223</pub-id><pub-id pub-id-type="pmid">23188834</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintavalle</surname><given-names>C</given-names></name><name><surname>Donnarumma</surname><given-names>E</given-names></name><name><surname>Fiore</surname><given-names>D</given-names></name><name><surname>Briguori</surname><given-names>C</given-names></name><name><surname>Condorelli</surname><given-names>G</given-names></name></person-group><article-title>Therapeutic strategies to prevent contrast-induced acute
kidney injury</article-title><source>Curr Opin Cardiol</source><year>2013</year><volume>28</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1097/HCO.0b013e3283653f41</pub-id><pub-id pub-id-type="pmid">24077605</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouzas-Mosquera</surname><given-names>A</given-names></name><name><surname>Recio-Mayoral</surname><given-names>A</given-names></name></person-group><article-title>Sodium bicarbonate, N-acetylcysteine, and saline for the
prevention of contrast-induced nephropathy</article-title><source>Am Heart J</source><year>2008</year><volume>155</volume><fpage>e31</fpage><pub-id pub-id-type="doi">10.1016/j.ahj.2008.01.022</pub-id><pub-id pub-id-type="pmid">18371455</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisbord</surname><given-names>SD</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Stone</surname><given-names>RA</given-names></name><name><surname>Kip</surname><given-names>KE</given-names></name><name><surname>Fine</surname><given-names>MJ</given-names></name><name><surname>Saul</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Associations of increases in serum creatinine with
mortality and length of hospital stay after coronary angiography</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>2871</fpage><lpage>2877</lpage><pub-id pub-id-type="doi">10.1681/ASN.2006030301</pub-id><pub-id pub-id-type="pmid">16928802</pub-id></element-citation></ref></ref-list></back></article>